One-year results of verteporfin PDT alone for the treatment of polypoidal choroidal vasculopathy in published studies compared with the combination therapy in this study
| Author | N | Baseline mean BCVA (letters) | Mean BCVA change (letters) | Results at Mo 12 | Results over 12 months | |||||||||
| Mo 3 | Mo 6 | Mo 9 | Mo 12 | BCVA gain ≥3 lines (% of eyes) | BCVA loss ≥3 lines (% of eyes) | Absence of FA leakage (% of eyes) | Complete polyp regression (% of eyes) | Polyp recurrence (% of eyes) | Re-treatment (% of eyes) | Mean No of PDT | Subretinal haemorrhage (% of eyes) | |||
| Chan5 | 22 | 48.5* | +7.5 | +6 | +5.5 | +6 | 45.5 | 4.5 | 90.5 | 95.5 | 4.5 | 40.9 | 1.6 | 18.2 |
| Silva6 | 21 | 37† | NA | NA | NA | +1 | 28.6 | 14.3 | 66.7 | NA | 4.7 | 95.2 | 2.9 | 4.7 |
| Akaza8 | 35 | 51.5 | +1.5 | 0 | −1 | −1.5 | NA | NA | 74.3 | 82.9 | 8.6 | NA | 2.2 | 8.6 |
| Eandi9 | 30 | 55† | NA | +3 | NA | +3 | 50.0 | 20.0 | 98.3 | NA | 50.0 | 50.0 | 2.2 | NA |
| Mitamura24 | 27 | 53.5 | +3 | +2.5 | NA | +3 | NA | NA | NA | NA | NA | 22.2 | 1.3 | NA |
| Gomi2 | 36 | 49.5† | NA | NA | NA | +6.8 | 25.0 | 8.3 | 86.1 | 86.1 | 5.6 | 38.9 | 1.5 | 19.4 |
| Kurashige10 | 41 | 57.5† | NA | NA | NA | +4.5 | 29.3 | 17.1 | NA | NA | NA | NA | NA | NA |
| Average | – | 50.4 | +4.0 | +3.8 | +2.3 | +3.3 | 35.7 | 12.8 | 73.5 | 87.8 | 14.7 | 49.4 | 2.0 | 12.7 |
| This study | 12 | 50.7† | +10.8 | +11.6 | +13.9 | +12.3 | 58.3 | 8.3 | 83.3 | 100 | 0 | 41.7 | 1.9 | 8.3 |
BCVA, best-corrected visual acuity (Snellen and logarithm of minimal angle of resolution visual acuity in each study was converted into letter scores for comparison); FA, fundus fluorescein angiography; Mo, month; NA, not available; PDT, photodynamic therapy.
The studies by Chan, Silva and Gomi were prospective, whereas the rest were retrospective; the superscripted number after each author's name indicates the reference number.
↵* Measured with Snellen chart.
↵† Measured with Early Treatment Diabetic Retinopathy Study chart (no data for the rest).